RCT: Adalimumab introduction vs. methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis.

Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study – The Lancet Rheumatology (link to abstract – $ for full-text)

Commentary: Adalimumab Addition vs. Methotrexate Escalation in Psoriatic Arthritis – RheumNow

Commentary on Twitter

https://twitter.com/TheLancetRheum/status/1498245286795390976